- Home
- RCS vs VNDA Comparison
RCS vs VNDA Comparison
Compare RCS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- VNDA
- Stock Information
- Founded
- RCS 1994
- VNDA 2002
- Country
- RCS United States
- VNDA United States
- Employees
- RCS N/A
- VNDA N/A
- Industry
- RCS Investment Managers
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- RCS Finance
- VNDA Health Care
- Exchange
- RCS Nasdaq
- VNDA Nasdaq
- Market Cap
- RCS 292.8M
- VNDA 282.8M
- IPO Year
- RCS N/A
- VNDA 2006
- Fundamental
- Price
- RCS $6.22
- VNDA $4.98
- Analyst Decision
- RCS
- VNDA Strong Buy
- Analyst Count
- RCS 0
- VNDA 2
- Target Price
- RCS N/A
- VNDA $16.50
- AVG Volume (30 Days)
- RCS 141.1K
- VNDA 751.6K
- Earning Date
- RCS 01-01-0001
- VNDA 05-07-2025
- Dividend Yield
- RCS 10.12%
- VNDA N/A
- EPS Growth
- RCS N/A
- VNDA N/A
- EPS
- RCS N/A
- VNDA N/A
- Revenue
- RCS N/A
- VNDA $198,772,000.00
- Revenue This Year
- RCS N/A
- VNDA $14.36
- Revenue Next Year
- RCS N/A
- VNDA $44.53
- P/E Ratio
- RCS N/A
- VNDA N/A
- Revenue Growth
- RCS N/A
- VNDA 3.18
- 52 Week Low
- RCS $4.51
- VNDA $3.71
- 52 Week High
- RCS $6.31
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- RCS 41.83
- VNDA 58.23
- Support Level
- RCS $6.21
- VNDA $4.84
- Resistance Level
- RCS $6.40
- VNDA $5.10
- Average True Range (ATR)
- RCS 0.14
- VNDA 0.24
- MACD
- RCS 0.01
- VNDA 0.02
- Stochastic Oscillator
- RCS 27.71
- VNDA 76.40
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.